Eyelash trichomegaly following treatment with erlotinib in a non‑small cell lung cancer patient: A case report and literature review

Wang,Shan‑Bing; Lei,Kai‑Jian; Liu,Jia‑Pei; Jia,Yu‑Ming

doi:10.3892/ol.2015.3265

Eyelash trichomegaly following treatment with erlotinib in a non‑small cell lung cancer patient: A case report and literature review

Authors:
- Shan‑Bing Wang
- Kai‑Jian Lei
- Jia‑Pei Liu
- Yu‑Ming Jia
View Affiliations

Affiliations: Department of Oncology, The Second People's Hospital of Yibin, Yibin, Sichuan 644000, P.R. China, Department of Laboratory Medicine, The Second People's Hospital of Yibin, Yibin, Sichuan 644000, P.R. China
Published online on: May 26, 2015 https://doi.org/10.3892/ol.2015.3265
Pages: 954-956

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inhibitors of epidermal growth factor receptor (EGFR), including tyrosine kinase inhibitors (TKIs), present significant clinical benefits in the treatment of non‑small cell lung cancer (NSCLC), particularly in patients with an EGFR mutation. However, TKI treatment also results in unwanted cutaneous toxic side effects, such as a skin rash. Eyelash trichomegaly is rarely reported as a side effect; however, it causes cosmetic issues or eyeball irritation in patients, which may result in the early termination of TKI treatment. Therefore, although TKI‑induced eyelash trichomegaly is rare, it should be considered carefully by lung cancer physicians. The present study reported a case of erlotinib‑induced eyelash trichomegaly in a 65‑year‑old Chinese female patient suffering from NSCLC with an EGFR mutation. To the best of our knowledge, this is the first reported case of erlotinib‑induced trichomegaly in a Chinese patient.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
3	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
4	Braiteh F, Kurzrock R and Johnson FM: Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol. 26:3460–3462. 2008. View Article : Google Scholar : PubMed/NCBI
5	Jeon SH, Ryu JS, Choi GS, et al: Erlotinib induced trichomegaly of the eyelashes. Tuberc Respir Dis (Seoul). 74:37–40. 2013. View Article : Google Scholar : PubMed/NCBI
6	Khozin S, Blumenthal GM, Jiang X, et al: U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. Oncologist. 19:774–779. 2014. View Article : Google Scholar : PubMed/NCBI
7	Gray H: Trichomegaly or movie lashes. Stanford Med Bull. 2:157–158. 1944.
8	Oliver GL and McFarlane DC: Congenital trichomegaly: With associated pigmentary degeneration of the retina, dwarfism, and mental retardation. Arch Ophthalmol. 74:169–171. 1965. View Article : Google Scholar : PubMed/NCBI
9	Kline AD, Krantz ID, Sommer A, et al: Cornelia de Lange syndrome: Clinical review, diagnostic and scoring systems and anticipatory guidance. Am J Med Genet A. 143A:1287–1296. 2007. View Article : Google Scholar : PubMed/NCBI
10	Ziakas NG, Jogiya A and Michaelides M: A case of familial trichomegaly in association with oculocutaneous albinism type 1. Eye (Lond). 18:863–864. 2004. View Article : Google Scholar : PubMed/NCBI
11	Cohen PR, Escudier SM and Kurzrock R: Cetuximab-associated elongation of the eyelashes: Case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. Am J Clin Dermatol. 12:63–67. 2011. View Article : Google Scholar : PubMed/NCBI
12	Pascual JC, Bañuls J, Belinchon I, Blanes M and Massuti B: Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol. 151:1111–1112. 2004. View Article : Google Scholar : PubMed/NCBI
13	Pucci N, Novembre E, Lombardi E, et al: Long eyelashes in a case series of 93 children with vernal keratoconjunctivitis. Pediatrics. 115:e86–e91. 2005.PubMed/NCBI
14	Alpsoy E: Hypotrichosis, long eyelashes and atopic dermatitis: A new syndrome? J Eur Acad Dermatol Venereol. 18:374–375. 2004. View Article : Google Scholar : PubMed/NCBI
15	Carser JE and Summers YJ: Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer. J Thorac Oncol. 1:1040–1041. 2006. View Article : Google Scholar : PubMed/NCBI
16	Iacovelli R, Palazzo A, Trenta P, et al: Trichomegaly of the eyelashe induced by erlotinib therapy. Lung Cancer. 64 (Suppl 1):S59–2009. View Article : Google Scholar
17	Lane K and Goldstein SM: Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg. 23:65–66. 2007. View Article : Google Scholar : PubMed/NCBI
18	Vergou T, Stratigos AJ, Karapanagiotou EM, et al: Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol. 63:e56–e58. 2010. View Article : Google Scholar : PubMed/NCBI
19	Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001. View Article : Google Scholar : PubMed/NCBI
20	Hirsch FR and Bunn PA Jr: EGFR testing in lung cancer is ready for prime time. Lancet Oncol. 10:432–433. 2009. View Article : Google Scholar : PubMed/NCBI
21	Miller VA, Riely GJ, Zakowski MF, et al: Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 26:1472–1478. 2008. View Article : Google Scholar : PubMed/NCBI
22	Sequist LV, Martins RG, Spigel D, et al: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
23	Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
24	Petrelli F, Borgonovo K, Cabiddu M, Lonati V and Barni S: Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials. Lung Cancer. 78:8–15. 2012. View Article : Google Scholar : PubMed/NCBI
25	Bouché O, Brixi-Benmansour H, Bertin A, Perceau G and Lagarde S: Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol. 16:1711–1712. 2005. View Article : Google Scholar
26	Shah NT, Kris MG, Pao W, et al: Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol. 23:165–174. 2005. View Article : Google Scholar : PubMed/NCBI